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Abstract 
Cancer cells are able to spontaneously fuse with normal host cells, including endothelial 
cells, and such fusions may strongly modulate the biological behaviour of tumors. 
However, the underlying mechanisms are unknown. We now show that human breast 
cancer cell lines and over a third of human breast cancers express syncytin, an 
endogenous retroviral envelope protein, previously implicated in fusions between 
placental trophoblast cells. Additionally, endothelial cells and cancer cells are shown to 
express ASCT-2, a receptor for syncytin. Syncytin antisense treatment decreases 
syncytin expression and inhibits fusions between breast cancer cells and endothelial 
cells. Moreover, a syncytin inhibitory peptide also inhibits fusions between cancer cells 
and endothelial cells. These results are the first to show that syncytin is expressed by 
human cancer cells and is involved in cancer-endothelial cell fusions. 
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Introduction 
A number of cell fusions occur during normal development. These include the fusion 
between the sperm and the egg cell and continue with fusions between placental 
trophoblasts to form syncytiotrophoblasts, between myoblasts to form muscle fibers and 
between macrophages to form osteoclasts [1]. Recently, it was shown that the human 
endogenous retroviral envelope protein syncytin (env-W) is involved in fusions between 
placental trophoblasts [2, 3]. Such fusions result in the formation of 
syncytiotrophoblasts and have been shown to involve the expression of a syncytin 
receptor, the neutral amino acid transporter ASCT-2, also referred to as the D-type 
retroviral receptor [2]. Although many endogenous retroviral sequences have 
degenerated during evolution, the syncytin sequence appears to have been conserved 
due to its ability to contribute to reproductive functions. Several studies have shown that 
cancer cells may spontaneously fuse with normal host cells in vitro (4, 5, 6-9) and in 
vivo [5, 10-13]. Such fusions result in cell hybrids containing an admixture of the 
parental genomes [5, 11]. In hybrids formed from fusions induced to occur between 
cancer cells and normal cells tumorogenicity is usually suppressed [14-18], due to 
activation of tumor suppressor genes contributed by the normal fusion partner [reviewed 
in 18]. However, in some cases, as for instance the formation of hybridomas producing 
monoclonal antibodies, tumorogenicity is not suppressed [19, for overviews see 4, 20, 
21]. Moreover, tumor suppression has been shown to be absent in hybrids formed from 
cells having a dominant negative mutation in p53 or expressing specific oncogenes [22]. 
The mechanisms by which cancer cells can spontaneously fuse with host cells are 
currently not understood, but are important since such fusions modify the biological 
behaviour of the ensuing hybrids. Moreover, the possible occurrence of spontaneous 
fusions betweeen cancer cells themselves [8] may contribute to aneuploidy and altered 
biological behaviour. 
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Previously, we reported that human breast cancer cells are able to spontaneously fuse 
with endothelial cells to form hybrid cells expressing protein and chromosomal markers 
characteristic of both parent cell lines [5]. Initially, heterokaryons appeared but, 
subsequently, mitotic figures and synkaryons, containing an admixture of the parental 
genomes in a single nucleus were observed [5]. In addition, studies in nude mice 
revealed that intravenous injection of metastasizing breast cancer (MDA-MB-231) cells 
resulted in the formation of hybrid cells containing both human and mouse 
chromosomes and showing endothelial cell characteristics [5]. Recent data suggest that 
similar fusions may also occur in man [reviewed in 4, 20 and 21]. We now demonstrate 
that the fusogenic protein syncytin is expressed in breast cancers and in breast cancer 
cell lines and also show that endothelial cells, as well as cancer cells, express the 
syncytin receptor ASCT-2. Moreover, antisense-mediated downregulation of syncytin 
expression, as well as a syncytin inhibitory peptide, inhibits fusions between breast 
cancer cells and endothelial cells. This demonstrates that the requirements for cancer-
endothelial cell fusions are present in many cases of human breast cancer and provides 
direct proof that syncytin is involved in such fusions. 
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Materials and methods 
Cell culture 
MCF-7, MDA-MB-231, human umbilical vein endothelial cells (HUVECs) and calf 
pulmonary artery endothelial (CPAE) cells were cultured as described [5, 23]. MCF-7 
cells were transfected with a previously characterized [25] phosphorthioate-protected 
syncytin antisense oligonucleotide (env-W 758-777) or with a scrambled control 
oligonucleotide [25] using oligofectamine (Invitrogen, Carlsbad, CA). After 48 h, MCF-
7 cells were either extracted for protein and RNA or were trypsinized, allowed to 
recover for 1 h and then co-cultured for 24 h with HUVECs or CPAE cells in chamber 
slides (Nalge Nunc Int., Naperville, IL). Additionally, MCF-7 cells were cocultured 
with HUVECs for 24 h in the presence of 5 µg/ml of a synthetic syncytin peptide (Ross-
Petersen, Hørsholm, Denmark), previously shown to inhibit syncytin-mediated fusions 
[24]. Control cells were incubated with equivalent concentrations of a control peptide 
(C-peptide(3-33), Sigma, St. Louis, MO) as well as without any peptide. Cells were 
fixed in 3.7 % paraformaldehyde in phosphate-buffered saline and permeabilized in 
0.1% triton X-100 or were left unpermeabilized. 
Immunocytochemistry and cell fusion assays 
Tumors from 165 female patients with ductal breast cancers without axillary lymph 
node involvement were fixed in 10% buffered formalin and embedded in paraffin. 
Deparaffinized sections underwent antigen retrieval by microwaving and were stained 
with rabbit antisera to the extracellular domain of syncytin (pab-10109, Orbigen, San 
Diego, CA) or to ASCT-2 (Chemicon, Temecula, CA). The site of antigen-antibody 
reaction was revealed by biotin-labeled antirabbit IgG followed by peroxidase-labeled 
streptavidin (Dako, Glostrup, Denmark) and development in diaminobenzidine. Nuclei 
were counterstained with haematoxylin. Controls included use of antisera preabsorbed 
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with the immunizing peptide (syncytin peptide was custom-synthesized by Ross-
Petersen and the ASCT-2 peptide was purchased from Chemicon). Monoclonal anti-
CD31 antibodies (Dako) were used in combination with rabbit anti-ASCT-2 antibodies, 
using detection with species-specific antibodies labeled with Alexa-594 or Alexa-488 
(Molecular Probes, Eugene, OR), respectively. Live MCF-7 cells and MCF-7 cells, 
fixed without permeabilization, were stained with the syncytin antiserum followed by 
Alexa-488-labeled antirabbit IgG (Molecular Probes). For quantitating cell fusions, 
specimens were stained for double immunofluorescence using monoclonal antibodies 
recognizing vimentin (3B4, IgG2a) and cytokeratin (pancytokeratin; IgG1) (Dako) 
followed by subclass-specific second antibodies labeled with Alexa-488 (anti-IgG2a) or 
Alexa-594 (anti-IgG1) (Molecular Probes) [5]. Nuclei were stained with bisbenzimide 
(Hoechst 33258, Sigma).  Controls, including use of type-matched monoclonal 
antibodies, as well as conventional staining controls were negative. Fused cells 
(cytokeratin and vimentin double-positive cells) were counted in blind-coded specimens 
and results were expressed as a percentage of fused cells versus unfused cells. In each 
experiment between 8 and 13 coded samples of each kind were counted and each 
experiment was repeated at least twice. The Mann-Whitney U-test was used for 
statistical comparisons.  
SDS-PAGE and immunoblotting  
Extraction, SDS-PAGE and electroblotting were performed as described [26]. 
Antibodies to syncytin (Orbigen) and to HER-2 (Pharmingen, BD Biosciences, 
Heidelberg, Germany) were used in combination with chemiluminescent detection and 
the intensities of the bands quantitated using NIH Image software [26]. Syncytin protein 
levels were expressed relative to HER-2 protein levels. 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR): Total RNA was 
prepared using the TRIZOL reagent. Reverse transcription employed the Superscript II 
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kit (Life Technologies) following the manufacturer’s recommendation for random 
hexamer RT and PCR except that 2.5 units of AmpliTaq polymerase were used. Forty 
cycles of PCR (annealing temperature 57°C, 1.5 mM MgCl2) were used. For detection 
of syncytin transcripts primer A (CCGCTGAAAGAGGGGGAA) was used as upstream 
and primer B (TAGAGGTTGTGCAGCTGAGA) was used as downstream primer [27], 
producing an amplicon of 400 base pairs while bovine ASCT-2 was amplified using 
primer C (TGCTGACACCTGTGAGAAGG) as upstream and primer D 
(CACAGCCACAGCCACTAAAA) as downstream primer, producing an amplicon of 
491 base pairs. Human ASCT-2 was amplified using primer E 
(GACCGTACGGAGTCGAGAAG) as upstream and primer F 
(GGGACGCAGCAGAACATTAT) as downstream primer, producing an amplicon of 
445 base pairs. PCR products were size fractionated by agarose gel electrophoresis. 
Controls for lack of genomic contamination included omission of RT from the reaction 
as well as use of intron-spanning primers detecting Hras (primer G: 
CCAGCTGATCCAGAACCATT and primer H: AGCCAGGTCACACTTGTTCC), 
producing an amplicon of 301 base pairs from cDNA and of 702 base pairs from 
genomic DNA, respectively. PCR products were sequenced by DNA Technology 
(Aarhus, Denmark). 
Real-time RT-PCR  
PCR was performed on a LightCycler (Roche) using SYBR green I Fast start kit 
(Roche) as described [26], using primers A and B for syncytin and primers for HER-2 
[26]. Syncytin mRNA levels were expressed relative to HER-2 mRNA levels. 
8 
Results 
Syncytin is expressed by breast cancer cells and ASCT-2 is expressed both by 
cancer cells and by endothelial cells 
Reverse transcriptase-polymerase chain reaction (RT-PCR) of RNA isolated from 
MCF-7 and MDA-MB-231 breast cancer cells revealed amplicons of the expected size 
(400 base pairs) from both cancer cell lines (Fig. 1A). No amplicon was obtained from 
endothelial cells. Exclusion of reverse transcriptase and use of intron-spanning primers 
documented lack of genomic contamination. Sequencing of the RT-PCR products 
revealed 99 % (MCF-7) and 82% (MDA-MB-231) homology to syncytin. 
Immunoblotting using an antiserum against the extracellular domain of syncytin 
revealed a 62-kDa immunoreactive band in extracts of MCF-7 and MDA-MB-231 cells 
(Fig. 1B), corresponding in size to a syncytin component present in the placenta [27]. 
Immunofluorescence staining of non-permeabilized MCF-7 cells showed that syncytin 
immunoreactivity was exposed on the external cell surface (Fig. 1C). 
Immunocytochemistry showed that 63 out of 165 human breast cancer specimens (38%) 
contained cancer cells that reacted for syncytin (Fig. 2A). A variable number of cancer 
cells were stained in individual tumors. Preabsorption of the antibody with the 
immunizing peptide eliminated staining (Fig. 2B). 
Immunofluorescence staining demonstrated expression of the syncytin receptor ASCT-2 
in endothelial cells as well as in cancer cells (Fig 2C). Absorption of the antiserum with 
the immunizing peptide eliminated staining. Double immunofluorescence for ASCT-2 
and CD31 confirmed that endothelial cells expressed ASCT-2. RT-PCR of RNA 
extracted from human endothelial (HUVECs) and breast cancer (MCF-7, MDA-MB-
231) cells revealed an amplicon of the size expected from human ASCT-2 mRNA (445 
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base  pairs; data not shown). Additionally, RT-PCR of RNA from bovine endothelial 
(CPAE) cells demonstrated an amplicon of the size expected (491 base pairs) from 
bovine ASCT-2 mRNA (Fig 1A). 
Antisense downmodulation of syncytin expression inhibits fusions between breast 
cancer cells and endothelial cells 
Treatment of MCF-7 cells with a phosphorthioate-protected syncytin antisense 
oligonucleotide decreased syncytin mRNA levels (by 33.8 ± 5.0 % as compared to a 
control, scrambled phosphorthioate oligo) and protein levels (by 38.2 ± 13.2 %). Levels 
were expressed relative to control mRNA/protein (HER-2) and therefore reflect a 
specific effect on syncytin expression. Transfected cells were co-cultured with 
HUVECs or with CPAE cells for 24 h and were then assayed for the frequency of 
cancer-endothelial cell fusion [5]. Briefly, co-cultures were fixed and triple-stained for 
vimentin (which is always expressed by HUVECs and by CPAE cells, but never by 
MCF-7 cells), cytokeratin (which is always expressed by MCF-7 cells, but never by 
HUVECs or CPAE cells) and DNA. After 24 h of co-culture, fused cells expressing 
both vimentin and cytokeratin and containing two or more nuclei were regularly 
observed in control co-cultures (Fig. 3A). Such cells were never observed when MCF-7, 
HUVECs or CPAE cells were cultured alone. Quantitations of the frequency of fused 
cells in blind-coded specimens documented that antisense treatment significantly 
(p<0.001) inhibited cancer-endothelial cell fusions (Fig. 3B). 
An inhibitory syncytin peptide inhibits fusions between breast cancer cells and 
endothelial cells 
The previous results indicated that downmodulation of syncytin expression by an 
antisense oligonucleotide, which previously has been evaluated in placental cells [25], 
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inhibited fusions between MCF-7 cells. However, since it is not always possible to 
conclude from antisense experiments that the effect observed reflects a direct action of 
the molecule targeted, we also examined effects of a syncytin peptide sequence, which 
previously has been shown to inhibit syncytin-mediated fusions [24]. MCF-7 cells, co-
cultured with HUVECs in the presence of this peptide, showed a highly significant 
(p<0.001) reduction in the number of cell fusions as compared to control cells that were 
exposed to equivalent concentrations of a control peptide (C-peptide) or were left 
untreated (Fig. 3). There was no difference in the number of fusions between cells 
grown in the presence or absence of C-peptide (p=0.6). Together, these results provide 
strong evidence that syncytin is directly involved in breast cancer-endothelial cell 
fusions. 
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Discussion 
These data are the first to show that syncytin is expressed by human cancer cells. Thus, 
two human breast cancer cell lines and over a third of human ductal breast cancers were 
found to express syncytin. Previously, studies have demonstrated that syncytin is 
expressed in the placenta, testicles [2, 3] and brain [28]. In order for syncytin to induce 
cell fusions, fusion partners must express an appropriate receptor such as the D-type 
retroviral receptor, ASCT-2 [2]. We therefore examined breast cancers and cultured 
endothelial cells for expression of ASCT-2 and detected expression in both cell types in 
vitro and in vivo. These results show that the molecular requirements for syncytin-
ASCT-2-mediated fusions are present in a significant number of breast cancer patients. 
Previously, we have documented that human breast cancer cells fuse with endothelial 
cells in a system validated by chromosomal and protein markers [5]. We therefore used 
this system to test whether syncytin was involved in mediating cancer-endothelial cell 
fusions. Syncytin expression was downmodulated by an antisense oligonucleotide 
sequence, which previously has been shown to specifically decrease syncytin expression 
and to inhibit fusions between placental trophoblasts [26]. The specificity of 
downmodulation was confirmed by simultaneous measurement of mRNA and protein 
levels of a reference (HER-2). Assays for cell fusions revealed that syncytin antisense 
treatment significantly inhibited cancer-endothelial cell fusions. Additionally, we also 
found that a syncytin inhibitory peptide [24] inhibited cancer-endothelial cell fusions. 
These results form definite evidence that syncytin is involved in mediating fusions 
between breast cancer cells and endothelial cells and suggest that spontaneous, 
syncytin-mediated fusions may occur in human breast cancer. 
It may be speculated that cancer-endothelial cell fusions occur in vivo when syncytin-
producing cancer cells come into direct contact with ASCT-2 expressing endothelial 
cells, e. g. during extravasation. Depending upon the genetic make-up of the fusion 
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partners such fusions may either result in the activation of tumor suppressors 
contributed by the normal fusion partner [14-18] or may result in hybrids with more 
aggressive properties [4, 20-22]. 
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LEGENDS TO FIGURES 
Fig. 1. Expression of syncytin by breast cancer cells and of ASCT-2 by endothelial 
cells. a. RT-PCR detects an amplicon of the size expected for syncytin (400 bp) in 
extracts of MCF-7 (lane 1) and MDA-231 cells (lane 2). Exclusion of RT yields no 
amplicon (shown for MCF-7 cells; lane 3) and ASCT-2 primers produce an amplicon of 
491 base pairs from CPAE cell extracts (lane 4). Positions of a base ladder (lane 5) are 
shown to the right. b. Immunoblotting detects a 62-kDa band in extracts of MCF-7 cells. 
c. Immunofluorescence staining for syncytin of live (antibody-impermeable) MCF-7 
cells. Note surface expression of syncytin.  
Fig 2. Immunocytochemical demonstration of syncytin and syncytin receptor (ASCT-2) 
expression in breast cancer. a. Immunoperoxidase staining for syncytin in human breast 
cancer specimen. Nuclei are stained blue with haematoxylin. Note syncytin 
immunoreactivity (brown) in scattered tumor cells. b. Adjacent section to the one shown 
in a, stained with antigen-preabsorbed antiserum. Note absence of staining. c. Human 
breast cancer specimen triple-stained for ASCT-2 (green fluorescence), the endothelial 
marker CD31 (red fluorescence) and DNA (blue fluorescence). Arrows point to 
endothelial cells that stain both for ASCT-2 and CD31 and, thus, emit orange 
fluorescence. To the right in the image, tumor cells that react for ASCT-2, but not for 
CD31, emit green fluorescence. 
Fig. 3. Fusions between breast cancer cells and endothelial cells depend upon syncytin. 
a. Control co-culture of MCF-7 and endothelial cells, triple-stained for vimentin (green), 
cytokeratin (red) and DNA (blue). Note a hybrid cell expressing both vimentin and 
cytokeratin (yellow). b. Quantitation of fused cells in co-cultures of MCF-7 and CPAE 
cells or of MCF-7 cells and HUVECs shows that the frequency of  cancer-endothelial 
cell fusions is inhibited by syncytin antisense, but not by control (scrambled) 
oligonucleotide treatment. c. Treatment with an inhibitory syncytin peptide inhibits 
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fusions between MCF-7 cells and HUVECs while a control peptide (C-peptide) has no 
effect. Three stars denote p<0.001.  



